Skip to main content
Disciplines
Automotive Business IT + Informatics Construction + Real Estate Electrical Engineering + Electronics Energy + Sustainability Insurance + Risk Finance + Banking Management + Leadership Marketing + Sales Mechanical Engineering + Materials
Events
DE
EN
Books
Journals
Topic Page
Marketing
Start single access now
Access for companies
EXTENDED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 12/2022

28-07-2022

Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men

Authors: Maria D. Jackson, Evelyn Walker, Marshall K. Tulloch-Reid

Published in: Quality of Life Research | Issue 12/2022

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

Purpose

Prostate cancer (PCa) and its treatment can impact health-related quality of life (HRQoL). There are few studies of HRQoL in long-term PCa survivors of African ancestry from low- and middle-income countries. We examined the effect of PCa treatment on HRQoL of Jamaican PCa survivors compared with cancer-free controls and explored the effect of demographic and clinical factors on these outcomes.

Methods

PCa survivors (n = 64) treated with and without ADT along with PCa-free controls (n = 88) from a case–control study of 10 years post enrolment. HRQoL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30). Effects of demographic and clinical variables on HRQoL on PCa and type of therapy were evaluated in multivariable linear regression models.

Results

HRQoL of PCa survivors (overall and by treatment group) indicated a high quality of life, comparable to PCa-free men. However, ADT-treated survivors had lower physical functioning that was of small clinical relevance compared with those not on ADT. Symptom burden scores of PCa survivors and controls were similar excluding fatigue and dyspnoea which were highest in men on ADT and controls. In multivariable models, PCa was not an important determinant of overall HRQoL, functioning or symptom burdens. Underlying medical conditions and marital status were the main contributors to HRQoL in PCa survivors.

Conclusion

PCa cancer status was not an independent determinant of long-term HRQoL in Jamaican men. Interventions addressing social factors and comorbid illnesses could improve HRQOL in long-term PCa survivors.
previous article The impact of care–recipient relationship type on health-related quality of life in community-dwelling older adults with dementia and their informal caregivers
next article The role of parental health and distress in assessing children’s health status

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

inform now
Appendix
Available only for authorised users
Literature
1.
Disease, G. B. D., Injury, I., & Prevalence, C. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392(10159), 1789–1858.CrossRef
2.
3.
Surbone, A., & Tralongo, P. (2016). Categorization of cancer survivors: Why we need it. Journal of Clinical Oncology, 34(28), 3372–3374.PubMedCrossRef
4.
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Hurwitz, M., Ippolito, J. E., Kane, C. J., Kuettel, M. R., Lang, J. M., McKenney, J., Netto, G., Penson, D. F., … Freedman-Cass, D. A. (2019). Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(5), 479–505.PubMedCrossRef
5.
Nguyen, P. L., Je, Y., Schutz, F. A., Hoffman, K. E., Hu, J. C., Parekh, A., Beckman, J. A., & Choueiri, T. K. (2011). Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA, 306(21), 2359–2366.PubMedCrossRef
6.
Galvao, D. A., Spry, N. A., Taaffe, D. R., Newton, R. U., Stanley, J., Shannon, T., Rowling, C., & Prince, R. (2008). Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU International, 102(1), 44–47.PubMedCrossRef
7.
Spry, N. A., Kristjanson, L., Hooton, B., Hayden, L., Neerhut, G., Gurney, H., Corica, T., Korbel, E., Weinstein, S., & McCaul, K. (2006). Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. European Journal of Cancer, 42(8), 1083–1092.PubMedCrossRef
8.
Groarke, A., Curtis, R., Skelton, J., & Groarke, J. M. (2020). Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience. PLoS ONE, 15(9), e0239469.PubMedPubMedCentralCrossRef
9.
Wu, H. S., & Harden, J. K. (2015). Symptom burden and quality of life in survivorship: A review of the literature. Cancer Nursing, 38(1), E29-54.PubMedCrossRef
10.
Adam, S., Doege, D., Koch-Gallenkamp, L., Thong, M. S. Y., Bertram, H., Eberle, A., Holleczek, B., Pritzkuleit, R., Waldeyer-Sauerland, M., Waldmann, A., Zeissig, S. R., Jansen, L., Rohrmann, S., Brenner, H., & Arndt, V. (2020). Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls-results from a population-based study. Supportive Care in Cancer, 28(6), 2875–2885.PubMedCrossRef
11.
Adam, S., Koch-Gallenkamp, L., Bertram, H., Eberle, A., Holleczek, B., Pritzkuleit, R., Waldeyer-Sauerland, M., Waldmann, A., Zeissig, S. R., Rohrmann, S., Brenner, H., & Arndt, V. (2019). Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study. European Journal of Cancer Care, 28(5), e13076.PubMedCrossRef
12.
Annunziata, M. A., Muzzatti, B., Flaiban, C., Gipponi, K., Carnaghi, C., Tralongo, P., Caruso, M., Cavina, R., & Tirelli, U. (2018). Long-term quality of life profile in oncology: A comparison between cancer survivors and the general population. Supportive Care in Cancer, 26(2), 651–656.PubMedCrossRef
13.
Arndt, V., Koch-Gallenkamp, L., Jansen, L., Bertram, H., Eberle, A., Holleczek, B., Schmid-Hopfner, S., Waldmann, A., Zeissig, S. R., & Brenner, H. (2017). Quality of life in long-term and very long-term cancer survivors versus population controls in Germany. Acta Oncologica, 56(2), 190–197.PubMedCrossRef
14.
Doege, D., Thong, M. S. Y., Weisser, L., Koch-Gallenkamp, L., Jansen, L., Bertram, H., Eberle, A., Holleczek, B., Nennecke, A., Pritzkuleit, R., Waldmann, A., Zeissig, S. R., Brenner, H., & Arndt, V. (2021). Health-related quality of life in very long-term cancer survivors 14–24 Years post-diagnosis compared to population controls: A population-based study. Cancers (Basel), 13(11), 2754.CrossRef
15.
Drummond, F. J., Kinnear, H., O’Leary, E., Donnelly, C., Gavin, A., & Sharp, L. (2015). Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship, 9(2), 361–372.PubMedCrossRef
16.
Gotze, H., Taubenheim, S., Dietz, A., Lordick, F., & Mehnert, A. (2018). Comorbid conditions and health-related quality of life in long-term cancer survivors-associations with demographic and medical characteristics. Journal of Cancer Survivorship, 12(5), 712–720.PubMedCrossRef
17.
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., de Haes, J. C., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRef
18.
Gandek, B., Sinclair, S. J., Kosinski, M., & Ware, J. E., Jr. (2004). Psychometric evaluation of the SF-36 health survey in Medicare managed care. Health Care Financing Review, 25(4), 5–25.PubMedPubMedCentral
19.
Kerleau, C., Guizard, A. V., Daubisse-Marliac, L., Heutte, N., Mercier, M., Grosclaude, P., Joly, F., & French Network of Cancer, R. (2016). Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. European Journal of Cancer, 63, 143–153.PubMedCrossRef
20.
Mols, F., van de Poll-Franse, L. V., Vingerhoets, A. J., Hendrikx, A., Aaronson, N. K., Houterman, S., Coebergh, J. W., & Essink-Bot, M. L. (2006). Long-term quality of life among Dutch prostate cancer survivors: Results of a population-based study. Cancer, 107(9), 2186–2196.PubMedCrossRef
21.
Jackson, M. D., Walker, S. P., Simpson, C. M., McFarlane-Anderson, N., Bennett, F. I., Coard, K. C., Aiken, W. D., Tulloch, T., Paul, T. J., & Wan, R. L. (2010). Body size and risk of prostate cancer in Jamaican men. Cancer Causes and Control, 21(6), 909–917.PubMedCrossRef
22.
Gleason, D. F., & Mellinger, G. T. (1974). Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. Journal of Urology, 111(1), 58–64.PubMedCrossRef
23.
Jackson, M. D., Tulloch-Reid, M. K., McCaw-Binns, A. M., Aiken, W., Ferguson, T. S., Bennett, N. R., Harrison, L., Badaloo, A., McGrowder, D., Grindley, A., Walker, E., & Anderson, S. G. (2020). Central adiposity at diagnosis may reduce prostate cancer-specific mortality in African-Caribbean men with prostate cancer: 10-year follow-up of participants in a case-control study. Cancer Causes and Control, 31(7), 651–662.PubMedCrossRef
24.
WHO. (2000). Obesity: Preventing and managing the global epidemic.
25.
Cocks, K., King, M. T., Velikova, G., de Castro Jr., G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2012). Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. European Journal of Cancer, 48(11), 1713–1721.PubMedCrossRef
26.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144.PubMedCrossRef
27.
Blank, T. O., & Bellizzi, K. M. (2006). After prostate cancer: Predictors of well-being among long-term prostate cancer survivors. Cancer, 106(10), 2128–2135.PubMedCrossRef
28.
Walker, R., Szanton, S. L., & Wenzel, J. (2015). Working toward normalcy post-treatment: A qualitative study of older adult breast and prostate cancer survivors. Oncology Nursing Forum, 42(6), E358-367.PubMedPubMedCentralCrossRef
29.
Bellizzi, K. M. (2004). Expressions of generativity and posttraumatic growth in adult cancer survivors. International Journal of Aging and Human Development, 58(4), 267–287.PubMedCrossRef
30.
Leach, C. R., Weaver, K. E., Aziz, N. M., Alfano, C. M., Bellizzi, K. M., Kent, E. E., Forsythe, L. P., & Rowland, J. H. (2015). The complex health profile of long-term cancer survivors: Prevalence and predictors of comorbid conditions. Journal of Cancer Survivorship, 9(2), 239–251.PubMedCrossRef
31.
Luo, Y. H., Yang, Y. W., Wu, C. F., Wang, C., Li, W. J., & Zhang, H. C. (2021). Fatigue prevalence in men treated for prostate cancer: A systematic review and meta-analysis. World Journal of Clinical Cases, 9(21), 5932–5942.PubMedPubMedCentralCrossRef
32.
Yates, P., Miaskowski, C., Cataldo, J. K., Paul, S. M., Cooper, B. A., Alexander, K., Aouizerat, B., Dunn, L., Ritchie, C., McCarthy, A., & Skerman, H. (2015). Differences in composition of symptom clusters between older and younger oncology patients. Journal of Pain and Symptom Management, 49(6), 1025–1034.PubMedCrossRef
33.
Savard, J., Hervouet, S., & Ivers, H. (2013). Prostate cancer treatments and their side effects are associated with increased insomnia. Psycho-Oncology, 22(6), 1381–1388.PubMedCrossRef
34.
Feng, L. R., Fuss, T., Dickinson, K., Ross, A., & Saligan, L. N. (2019). Co-occurring symptoms contribute to persistent fatigue in prostate cancer. Oncology, 96(4), 183–191.PubMedCrossRef
35.
Sammarco, A. (2009). Quality of life of breast cancer survivors: A comparative study of age cohorts. Cancer Nursing, 32(5), 347–356.PubMedCrossRef
36.
Forsythe, L. P., Alfano, C. M., Kent, E. E., Weaver, K. E., Bellizzi, K., Arora, N., Aziz, N., Keel, G., & Rowland, J. H. (2014). Social support, self-efficacy for decision-making, and follow-up care use in long-term cancer survivors. Psycho-Oncology, 23(7), 788–796.PubMedPubMedCentralCrossRef
37.
Nguyen, P. L., Alibhai, S. M., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015). Adverse effects of androgen deprivation therapy and strategies to mitigate them. European Urology, 67(5), 825–836.PubMedCrossRef
38.
Brundage, M., Sydes, M. R., Parulekar, W. R., Warde, P., Cowan, R., Bezjak, A., Kirkbride, P., Parliament, M., Moynihan, C., Bahary, J. P., Parmar, M. K., Sanders, K., Chen, B. E., & Mason, M. D. (2015). Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 Randomized Trial. Journal of Clinical Oncology, 33(19), 2151–2157.PubMedPubMedCentralCrossRef
39.
Moul, J. W., & Dawson, N. (2012). Quality of life associated with treatment of castration-resistant prostate cancer: A review of the literature. Cancer Investigation, 30(1), 1–12.PubMedCrossRef
40.
Geerkens, M. J. M., Pouwels, N. S. A., & Beerlage, H. P. (2020). The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostate cancer: A systematic review. Quality of Life Research, 29(4), 843–865.PubMedCrossRef
41.
Adam, S., Thong, M. S. Y., Martin-Diener, E., Camey, B., Egger Hayoz, C., Konzelmann, I., Mousavi, S. M., Herrmann, C., Rohrmann, S., Wanner, M., Staehelin, K., Strebel, R. T., Randazzo, M., John, H., Schmid, H. P., Feller, A., & Arndt, V. (2021). Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors-results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS). Supportive Care in Cancer, 29(11), 6259–6269.PubMedPubMedCentralCrossRef
42.
Pearson, E. J. M., Morris, M. E., di Stefano, M., & McKinstry, C. E. (2018). Interventions for cancer-related fatigue: a scoping review. European Journal of Cancer Care (Engl), 27(1), e12516.CrossRef
43.
Kim, M. S., Jung, S. I., Chung, H. S., Chang Hwang, E., & Kwon, D. (2021). Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study. Prostate International, 9(3), 132–139.PubMedCrossRef
44.
Gordon, L. G., Merollini, K. M. D., Lowe, A., & Chan, R. J. (2017). A Systematic review of financial toxicity among cancer survivors: We can’t pay the co-pay. Patient, 10(3), 295–309.PubMedCrossRef
45.
Pearce, A., Tomalin, B., Kaambwa, B., Horevoorts, N., Duijts, S., Mols, F., van de Poll-Franse, L., & Koczwara, B. (2019). Financial toxicity is more than costs of care: The relationship between employment and financial toxicity in long-term cancer survivors. Journal of Cancer Survivorship, 13(1), 10–20.PubMedCrossRef
46.
van Andel, G., Bottomley, A., Fossa, S. D., Efficace, F., Coens, C., Guerif, S., Kynaston, H., Gontero, P., Thalmann, G., Akdas, A., D’Haese, S., & Aaronson, N. K. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418–2424.PubMedCrossRef
Metadata
Title
Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men
Authors
Maria D. Jackson
Evelyn Walker
Marshall K. Tulloch-Reid
Publication date
28-07-2022
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 12/2022
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03202-2

Other articles of this Issue 12/2022

Quality of Life Research 12/2022 Go to the issue

OriginalPaper

Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures

OriginalPaper

Measurement properties of the Dutch PROMIS-29 v2.1 profile in people with and without chronic conditions

Letter to the Editor

Reply to: Concerns with study ABC

Review

Measurement properties and interpretability of the PROMIS item banks in stroke patients: a systematic review

Review

The patient-reported outcomes measurement information systems (PROMIS®) physical function and its derivative measures in adults: a systematic review of content validity

Letter to the Editor

Discussion on the assessment of functioning in people under 18 years of age